This technology presents an innovative approach to the treatment of Graft Versus Host Disease (GvHD) by harnessing the therapeutic potential of Pregnancy Specific Glycoproteins (PSG1 and PSG9). The method involves a novel administration technique for these glycoproteins, which had not been previously disclosed prior to the patent application. The technology holds promise in addressing the challenges associated with GvHD treatment, potentially offering new avenues for improving patient outcomes in this complex medical condition. To obtain detailed information about the methodology and the patent application, one should contact the Henry M. Jackson Foundation Inventor or their authorized representatives.